Bill cutting tax deductions for drug ads could help fund 'pill penalty' fix
A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct-to-consumer drug advertising, a bill that could generate savings to offset...
View ArticleVaxart says stop-work order was lifted on next-gen Covid vaccine
Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era initiative, allowing it to screen participants for a large mid-stage trial to...
View ArticleOctagon Therapeutics shuts down after 'unresolved biology questions'
Octagon Therapeutics is winding down operations, its CEO posted on LinkedIn on Monday. The biotech, with operations in Cambridge, MA, and Providence, RI, had been working on programs in autoimmune and ...
View ArticleFDA delays decision date for small biotech, raising questions about impact of...
The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may be affecting key regulatory decisions ...
View ArticleNovartis Q1 earnings: Company raises 2025 bar after beating sales expectations
Novartis is starting the year on a strong note as several of its core medicines beat Wall Street’s sales projections, prompting the drugmaker to shift its full-year guidance to a higher bar. In the...
View ArticleAstraZeneca posts another Truqap study fail, says China import tax could triple
AstraZeneca’s Truqap is 2-for-4 in its pivotal cancer trials. It said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim analysis ...
View ArticleBasil Systems raises $11.5M to help pharma navigate regulations
A startup built to help pharmaceutical and medical device companies make sense of regulatory requirements just raised $11.5 million in new funding, Endpoints News has learned exclusively. Launched in...
View ArticlePfizer plans more cost cuts, expanding total savings to $7.7B
Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned reductions. The new round of cuts disclosed Tuesday is part of Pfizer’s "cost...
View ArticleAstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs near
With the industry on tenterhooks on what the pharma-specific tariffs may look like, AstraZeneca and Novartis said Tuesday that their local production capacity will be key in sidestepping these levies....
View ArticleHims and Novo Nordisk partner to offer discounted Wegovy
In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight loss drug Wegovy at a discounted price directly through the telehealth...
View ArticleDevoted Health 2024 financials reveal revenue growth
Health insurance startup Devoted Health is a bright spot in the volatile market for private health plans for seniors, growing membership and revenue while narrowing its operating losses in 2024, even...
View ArticleWith a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnership
Creyon Bio, a small San Diego biotech startup working on oligonucleotides, has signed up Eli Lilly as its first big pharma partner. The Indianapolis giant, which has placed more of an emphasis on...
View ArticleAbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder...
Plus, news about the Novo Nordisk Foundation and Tonix: AbbVie’s Rinvoq gets label expansion: The blockbuster JAK inhibitor won approval in the US to treat adults with giant cell arteritis, an ...
View ArticleFDA won't reorganize medical product centers, Makary says in interview
The FDA plans to consolidate some administrative functions, but won't embark on a wholesale reorganization of the review centers that oversee drugs, biologics and medical devices, FDA Commissioner...
View ArticleFDA approves Abeona’s skin disease cell therapy
Abeona Therapeutics received FDA approval for its cell therapy to treat “butterfly skin,” a rare genetic disease that causes fragile skin and wounds. And its price tag makes it one of the most...
View ArticleMerck plans to shift Keytruda production to the US
Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on its plans to move production to the US to mitigate the impact of potential...
View ArticleInside Devoted Health’s 2024 financials
Every spring I ask Shelby a very fun question: Is it time to look at insurance filings? This year, that included combing through the 33 individual filings. Together, they give a rare glimpse into how ...
View ArticleHow pharma is reacting to ‘Liberation Day’: Endpoints livestream
Today at 12 p.m. ET, we’re going to try something new. We’re taking Post-Hoc — our newsletter that brings you insight from our journalists — and streaming it live! We'll talk about how the drug...
View ArticlePfizer’s Bourla projects confidence that tariffs will focus on US adversaries
With the Trump administration's planned pharma tariffs on the horizon, Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented....
View ArticleArtios cancer drug shrinks subset of tumors in early study
Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced cancer. It’s the first big data reveal for...
View ArticleNoma Therapy raises $4M for virtual ketamine-assisted therapy
Noma Therapy, a virtual ketamine-assisted therapy provider, has launched with $4.25 million in funding, Endpoints News learned exclusively. The Colorado-based startup is backed by health tech studio...
View ArticleGSK's supply chain 'reset' after Haleon spinoff to ease tariff impact, CEO says
GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential pharma-specific tariffs. When the drugmaker went through its “demerger” with the ...
View ArticleNovartis to buy Regulus Therapeutics for up to $1.7B
Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday. This is more than double Regulus’ share price at Tuesday’s close ...
View Article